Effects of barbiturates on human platelet aggregation differ depending on their chemical structures

Area of Science:

• Pharmacology
• Hematology
• Biochemistry

Background:

• The impact of barbiturates on human platelet function remains incompletely understood.
• Previous research has established the effects and mechanisms of thiopental, thiamylal, and pentobarbital on platelets.

Purpose of the Study:

• To investigate the effects of various barbiturates on human platelet aggregation.
• To elucidate the underlying mechanisms of barbiturate action on platelets.
• To explore the structure-function relationship of barbiturates in modulating platelet activity.

Main Methods:

• Examined barbiturates including amobarbital, butalbital, secobarbital, barbital, phenobarbital, metharbital, and primidone.
• Measured human platelet aggregation induced by adenosine diphosphate (ADP), epinephrine, and a thromboxane A2 analog (STA2) using light-transmission aggregometry.
• Assessed cytosolic free calcium concentration ([Ca2+]i) and inositol 1,4,5-trisphosphate (IP3) formation to determine mechanisms.

Main Results:

• Amobarbital, butalbital, and secobarbital suppressed platelet aggregation and STA2-induced [Ca2+]i increase, independent of extracellular calcium.
• These inhibitory effects were not associated with altered STA2-induced IP3 formation.
• Barbital, phenobarbital, metharbital, and primidone did not affect platelet aggregation at concentrations up to 1 mM.

Conclusions:

• Amobarbital, butalbital, and secobarbital inhibit platelet aggregation by reducing cytosolic calcium levels without impacting IP3 formation.
• The observed antiplatelet effects may lack clinical relevance due to the high concentrations required.
• Barbiturate-induced effects on platelet aggregation are dependent on their chemical structures.